NCT Number: NCT00094081
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Foundation for Cancer Research and Education, Phoenix, Arizona, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.
- Stage III or IV disease (excluding T1N1, and T2N1).
- ECOG performance status less than or equal to 2.
- Absolute neutrophil count at least 1.5 X 10^9/L, platelet count at least 100 X 10^9/L, and hemoglobin > 9g/dL.
- Serum bilirubin < 1.25 times ULN and AST/ALT < 2.5 times ULN.
- Calculated creatinine clearance (Cockcroft-Gault) > 55 mL/min.
Exclusion criteria
- Metastatic Disease
Treatment and study plan
Cisplatin
DrugRadiation Therapy
ProcedurePrimary outcomes
-
Overall survival.
Secondary outcomes
-
Time to locoregional failure.
Sponsors and collaborators
Lead sponsor
Sanofi
Industry
Registry information
Official study title
Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer
Important dates
- Study start
- 2002
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Oct 14, 2004
- Registry last updated
- Feb 15, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity
NCT02442375
Carcinoma, Carcinoma, Squamous Cell
Amsterdam, Netherlands
View Trial DetailsDe-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
NCT02281955
Carcinoma, Carcinoma, Squamous Cell
Gainesville, Florida, United States
View Trial DetailsDe-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
NCT01530997
Carcinoma, Carcinoma, Squamous Cell
Colorado Springs, Colorado, United States
View Trial DetailsP53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
NCT03077243
Carcinoma, Carcinoma, Squamous Cell
Gainesville, Florida, United States
View Trial Details